The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "baricitinib"

Search results for: baricitinib

Long-Term Safety of Baricitinib for RA

December 14, 2020 • By Michele B. Kaufman, PharmD, BCGP

Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.... [Read More]

Filed Under: ACR Convergence, DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, baricitinib, JAK inhibitor, Rheumatoid Arthritis (RA)

Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2

December 3, 2020 • By Michele B. Kaufman, PharmD, BCGP

The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.... [Read More]

Filed Under: Drug Updates Tagged With: baricitinib, COVID-19, FDA, remdesivir, U.S. Food and Drug Administration (FDA)

Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market

May 11, 2020 • By Michele B. Kaufman, PharmD, BCGP

Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…... [Read More]

Filed Under: Drug Updates, Safety Tagged With: baricitinib, COVID-19, Drug Safety, ranitidine, U.S. Food and Drug Administration (FDA)

Baricitinib: Early vs. Late Treatment Outcomes in RA Patients

August 5, 2019 • By Michele B. Kaufman, PharmD, BCGP

Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: baricitinib, EULAR, Rheumatoid Arthritis (RA)

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

June 25, 2019 • By Lara C. Pullen, PhD

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…... [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: adalimumab, baricitinib, Rheumatoid Arthritis (RA), washout

Long-Term Data Show Baricitinib Is Safe & Effective for RA

December 17, 2018 • By Michele B. Kaufman, PharmD, BCGP

Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: baricitinib, Rheumatoid Arthritis (RA)

Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE

September 6, 2018 • By Lara C. Pullen, PhD

A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…... [Read More]

Filed Under: Conditions, SLE (Lupus) Tagged With: baricitinib, organ damage, rash, systemic lupus erythematosus (SLE)

FDA Approves Baricitinib for RA Patients

June 25, 2018 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: baricitinib, FDA approval, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration (FDA)

FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

May 8, 2018 • By Michele B. Kaufman, PharmD, BCGP

The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: baricitinib, Food and Drug Administration, hemophagocytic lymphohistiocytosis, HLH, lamotrigine, U.S. Food and Drug Administration (FDA)

FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib

April 26, 2018 • By Tamara Mathias

(Reuters)—An experimental rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp. poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff says, the latest setback to a treatment regulators declined to approve last year. New data provided by the companies in a resubmission of their marketing… [Read More]

Filed Under: Drug Updates, Safety Tagged With: baricitinib, Drug Safety, FDA, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration (FDA)

  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.